Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares ('ADSs') of GlaxoSmithKline plc ('Company').
On 31 March 2015, the Company's Non-Executive Directors were allocated notional Ordinary Shares at a price of £15.66 per Ordinary Share, and notional ADSs at a price of $46.80 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2015 to 31 March 2015:
Non Executive Director |
Ordinary Shares |
No. of ADSs |
|
|
|
Sir Christopher Gent |
3,991.060 |
|
|
|
|
Professor Sir Roy Anderson |
458.972 |
|
|
|
|
Dr Stephanie Burns |
|
486.201 |
|
|
|
Stacey Cartwright |
339.240 |
|
|
|
|
Lynn Elsenhans |
|
1,103.464 |
|
|
|
Sir Philip Hampton |
339.240 |
|
|
|
|
Judy Lewent |
|
539.049 |
|
|
|
Sir Deryck Maughan |
|
1,479.741 |
|
|
|
Dr Daniel Podolsky |
|
1,109.806 |
|
|
|
Urs Rohner |
339.240 |
|
|
|
|
Tom de Swaan |
419.061 |
|
|
|
|
Jing Ulrich |
|
306.518 |
|
|
|
Hans Wijers |
339.240 |
|
|
|
|
The Company and the Non-Executive Directors were informed of these allocations on 1 April 2015.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
1 April 2015